Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Article in English | LILACS-Express | LILACS | ID: biblio-1565200

ABSTRACT

ABSTRACT Objective: To evaluate the seasonality of acute bronchiolitis in Brazil during the 2020-2022 season and compare it with the previous seasons. Methods: Data from the incidence of hospitalizations due to acute bronchiolitis in infants <1 year of age were obtained from the Department of Informatics of the Brazilian Public Health database for the period between 2016 and 2022. These data were also analyzed by macro-regions of Brazil (North, Northeast, Southeast, South, and Midwest). To describe seasonal and trend characteristics over time, we used the Seasonal Autoregressive Integrated Moving Averages Model. Results: Compared to the pre-COVID-19 period, the incidence of hospitalizations related to acute bronchiolitis decreased by 97% during non-pharmacological interventions (March 2020 - August 2021) but increased by 95% after non-pharmacological interventions relaxation (September 2021 - December 2022), resulting in a 16% overall increase. During the pre-COVID-19 period, hospitalizations for acute bronchiolitis followed a seasonal pattern, which was disrupted in 2020-2021 but recovered in 2022, with a peak occurring in May, approximately 4% higher than the pre-COVID-19 peak. Conclusions: This study underscores the significant influence of COVID-19 interventions on acute bronchiolitis hospitalizations in Brazil. The restoration of a seasonal pattern in 2022 highlights the interplay between public health measures and respiratory illness dynamics in young children.


RESUMO Objetivo: Avaliar a sazonalidade da bronquiolite aguda no Brasil durante a temporada 2020-2022 e compará-la com a das temporadas anteriores. Métodos: Os dados de incidência de internações por bronquiolite aguda em lactentes <1 ano de idade foram obtidos do Departamento de Informática da base de dados da Saúde Pública Brasileira para o período entre 2016 e 2022. Esses dados também foram analisados por macrorregiões do Brasil (Norte, Nordeste, Sudeste, Sul e Centro-Oeste). Para descrever características sazonais e de tendência ao longo do tempo, utilizamos o Modelo de Médias Móveis Integradas Autorregressivas Sazonais. Resultados: Em comparação com o período pré-COVID-19, a incidência de hospitalizações relacionadas com bronquiolite aguda diminuiu 97% durante as intervenções não farmacológicas (março de 2020 - agosto de 2021), mas aumentou 95% após a flexibilização das intervenções não farmacológicas (setembro de 2021 - dezembro de 2022), resultando no aumento geral de 16%. Durante o período pré-COVID-19, as hospitalizações por bronquiolite aguda seguiram um padrão sazonal, que foi interrompido em 2020-2021, mas recuperaram-se em 2022, com um pico ocorrido em maio, aproximadamente 4% superior ao pico pré-COVID-19. Conclusões: Este estudo ressalta a influência significativa das intervenções contra a COVID-19 nas hospitalizações por bronquiolite aguda no Brasil. A restauração de um padrão sazonal em 2022 sublinha a interação entre as medidas de saúde pública e a dinâmica das doenças respiratórias em crianças pequenas.

2.
Rev Paul Pediatr ; 43: e2023203, 2024.
Article in English | MEDLINE | ID: mdl-38985050

ABSTRACT

OBJECTIVE: To evaluate the seasonality of acute bronchiolitis in Brazil during the 2020-2022 season and compare it with the previous seasons. METHODS: Data from the incidence of hospitalizations due to acute bronchiolitis in infants <1 year of age were obtained from the Department of Informatics of the Brazilian Public Health database for the period between 2016 and 2022. These data were also analyzed by macro-regions of Brazil (North, Northeast, Southeast, South, and Midwest). To describe seasonal and trend characteristics over time, we used the Seasonal Autoregressive Integrated Moving Averages Model. RESULTS: Compared to the pre-COVID-19 period, the incidence of hospitalizations related to acute bronchiolitis decreased by 97% during non-pharmacological interventions (March 2020 - August 2021) but increased by 95% after non-pharmacological interventions relaxation (September 2021 - December 2022), resulting in a 16% overall increase. During the pre-COVID-19 period, hospitalizations for acute bronchiolitis followed a seasonal pattern, which was disrupted in 2020-2021 but recovered in 2022, with a peak occurring in May, approximately 4% higher than the pre-COVID-19 peak. CONCLUSIONS: This study underscores the significant influence of COVID-19 interventions on acute bronchiolitis hospitalizations in Brazil. The restoration of a seasonal pattern in 2022 highlights the interplay between public health measures and respiratory illness dynamics in young children.


Subject(s)
Bronchiolitis , COVID-19 , Hospitalization , Interrupted Time Series Analysis , Seasons , Humans , Brazil/epidemiology , Infant , Bronchiolitis/epidemiology , Bronchiolitis/therapy , Incidence , Hospitalization/statistics & numerical data , Hospitalization/trends , COVID-19/epidemiology , Infant, Newborn , Acute Disease
3.
Clin Infect Dis ; 72(12): 2071-2075, 2021 06 15.
Article in English | MEDLINE | ID: mdl-32986818

ABSTRACT

BACKGROUND: Interventions to tackle the coronavirus disease 2019 (COVID-19) pandemic may affect the burden of other respiratory diseases. Considering the repercussions of these unique social experiences to infant health, this study aims to assess the early impact of social distancing due to the COVID-19 pandemic in hospital admissions for acute bronchiolitis. METHODS: Data from hospitalizations of acute bronchiolitis in infants <1 year of age were obtained from the Department of Informatics of the Brazilian Public Health database for the period between 2016 and 2020. These data were also analyzed by macroregions of Brazil (North, Northeast, Southeast, South, and Midwest). To evaluate the effect of social distancing strategy on the incidence of acute bronchiolitis, the absolute and relative reductions were calculated by analyzing the yearly subsets of 2016 vs 2020, 2017 vs 2020, 2018 vs 2020, and 2019 vs 2020. RESULTS: There was a significant reduction in all comparisons, ranging from -78% (incidence rate ratio [IRR], 0.22 [95% confidence interval {CI}, .20-.24]) in 2016 vs 2020 to -85% (IRR, 0.15 [95% CI, .13-.16]) in 2019 vs 2020, for the data from Brazil. For analyses by macroregions, the reduction varied from -58% (IRR, 0.41 [95% CI, .37-.45]) in the Midwest in 2016 vs 2020 to -93% (IRR, 0.07 [95% CI, .06-.08]) in the South in 2019 vs 2020. CONCLUSIONS: There was a significant reduction in hospitalization for acute bronchiolitis in children <1 year old in Brazil, on the order of >70% for most analysis. Our data suggest an important impact of social distancing on reducing the transmission of viruses related to acute bronchiolitis. Such knowledge may guide strategies for prevention of viral spread.


Subject(s)
Bronchiolitis , COVID-19 , Brazil/epidemiology , Bronchiolitis/epidemiology , Bronchiolitis/prevention & control , Child , Hospitalization , Humans , Infant , Pandemics , Physical Distancing , SARS-CoV-2
4.
J Bras Pneumol ; 46(3): e20180376, 2020.
Article in Portuguese, English | MEDLINE | ID: mdl-32130359

ABSTRACT

OBJECTIVE: A significant proportion of the infants developed recurrent wheezing after an acute bronchiolitis (AB) event. Recent studies have demonstrated protection for recurrent wheeze and lower respiratory morbidity in infants treated with azithromycin during an acute respiratory wheezing. The aim of the present study was to test the hypothesis that administration of azithromycin during an AB event reduces subsequent wheezing and hospital re-admissions. METHODS: This is a secondary analysis of a randomized, double-blinded, placebo-controlled trial, including unpublished data of wheezing and hospitalizations during the initial 6 months following admission for acute viral bronchiolitis. The study was performed in a tertiary University hospital. Infants (<12 months of age) hospitalized with AB were randomized to receive either azithromycin or placebo, administered orally, for 7 days. Families were contacted by telephone at 3 and 6 months after the initial acute event and answered to a standardized questionnaire in order to identify recurrent wheezing and hospital readmissions. RESULTS: One hundred and four patients were included (Azithromycin group, n= 50; placebo group, n=54). Considering the total of patients contacted 3 months after hospitalization (n=70), the recurrence rate of wheezing in the azithromycin group was significantly lower than in the placebo group (RR = 0.48; CI = 0.24-0.98; p = 0.038). CONCLUSION: Azithromycin significantly reduces the risk of subsequent wheezing between 0 and 3 months after hospital admission due to acute bronchiolitis irrespective of the presence of respiratory syncytial virus.


OBJETIVO: Uma proporção significativa de lactentes desenvolve sibilância recorrente após um evento de bronquiolite aguda (BA). Estudos recentes demonstraram proteção para sibilância recorrente e menor morbidade respiratória em lactentes tratados com azitromicina durante uma crise de sibilância. O objetivo do presente estudo foi testar a hipótese de que a administração de azitromicina durante um evento BA reduz sibilos e reinternações hospitalares subsequentes. MÉTODOS: Trata-se de uma análise secundária de um estudo randomizado, duplo-cego, controlado por placebo, incluindo dados não publicados de sibilância e hospitalizações durante os seis meses iniciais após a internação por bronquiolite aguda. O estudo foi realizado em um hospital universitário terciário. Os bebês (<12 meses de idade) hospitalizados com BA foram randomizados para receber azitromicina ou placebo, administrados por via oral, por sete dias. As famílias foram contatadas por telefone aos três e seis meses após o evento agudo inicial, e responderam a um questionário padronizado para identificar sibilos recorrentes e reinternações hospitalares. RESULTADOS: Cento e quatro pacientes foram incluídos (grupo Azitromicina, n=50; grupo Placebo, n=54). Considerando o total de pacientes contatados com sucesso três meses após a hospitalização (n=70), a taxa de recorrência de sibilância no grupo da azitromicina foi significativamente menor do que no grupo placebo (RR=0,48; CI=0,24-0.98; p=0,038). CONCLUSÕES: A azitromicina reduziu significativamente o risco de sibilância subsequente entre zero e três meses após a admissão hospitalar por bronquiolite aguda.


Subject(s)
Azithromycin/therapeutic use , Bronchiolitis/drug therapy , Azithromycin/administration & dosage , Bronchiolitis/diagnosis , Hospitalization , Humans , Infant , Recurrence , Respiratory Sounds , Treatment Outcome
5.
PLoS One ; 15(1): e0228022, 2020.
Article in English | MEDLINE | ID: mdl-31990945

ABSTRACT

INTRODUCTION: Pertussis is an important public health problem worldwide, especially in infants. An increase in the incidence in many countries occurred after 2010, including Brazil. In 2013, dTpa vaccine was introduced in the Brazil national immunization schedule of pregnant women. The objective of this study was to evaluate the national trends in the incidence of pertussis in Brazil in children under 1 year old, and the impact of the introduction of dTpa vaccine during pregnancy. METHODS: The incidence of hospitalizations and non-hospitalized confirmed cases of pertussis in neonates (< 1 month age) and young infants (1 month-< 1 year age) were analyzed, comparing the incidence in pre maternal vaccination (2011-2013) with the post-vaccination (2015-2017). We used non-respiratory hospitalizations as comparison, during the same period. A database of the Brazilian Ministry of Health (DATASUS) was used to analyze cases from 2007 to 2017 and the subsets of 2011-2013 and 2015-2017, after Pertussis resurgence. The vaccination data was accessed through the link of the Information System of the National Immunization Program (pni.datasus.gov.br). RESULTS: Between 2007 and 2017, 17,818 children under one year of age were hospitalized due to pertussis in Brazil. In the pre maternal vaccination period 2011-2013, the mean annual incidence of non-hospitalized confirmed cases of pertussis in children under 1 month was 722.2 / 100,000 and in the period of 2015-2017 the average was 377.3 / 100,000, representing a decrease of 47.7% [IRR 0.52 (0.46-0.59)]. At those periods of time, the average incidence per year for children of one month-< 1 year aged was 64.9 / 100,000 (2011-2013) and 29.3 / 100,000 (2015-2017) [IRR 0.45 (CI 0.29-0.69)]. CONCLUSION: Vaccination of pregnant woman coincides with the reduction in the number of cases of pertussis in children under 1 month of age from 2015. Immunization of pregnant woman seems to have an important impact on the prevention of the disease in young infants who have not yet received their own pertussis vaccine.


Subject(s)
Hospitalization/statistics & numerical data , Immunization Programs/organization & administration , Pertussis Vaccine/administration & dosage , Vaccination/methods , Whooping Cough/prevention & control , Adult , Bordetella pertussis/drug effects , Bordetella pertussis/immunology , Brazil/epidemiology , Child , Databases, Factual , Female , Humans , Immunization Schedule , Incidence , Infant , Infant, Newborn , Male , Pregnancy , Pregnant Women , Whooping Cough/epidemiology , Whooping Cough/immunology
6.
Rev Paul Pediatr ; 38: e2018120, 2020.
Article in English, Portuguese | MEDLINE | ID: mdl-31778406

ABSTRACT

OBJECTIVE: To evaluate the trend of hospitalization for acute bronchiolitis in infants under one year of age, in the past eight years and after the implementation of the palivizumab immunization program in Brazil. METHODS: The study is a retrospective analysis of data on infants younger than one year of age, who were hospitalized with acute bronchiolitis between 2008 and 2015 in Brazil. The Brazilian National Health System database was used. The rates of hospitalization in the pre-implementation (2008-2012) and post-implementation (2014-2015) periods of the palivizumab immunization program were evaluated. The total number of admissions in the same period was used as a comparison. RESULTS: Between January 2008 and December 2015, 263,679 hospitalizations for bronchiolitis were recorded in infants younger than one year of age, 60% represented by boys. The incidence of hospitalization for bronchiolitis increased by 49% over this period (8.5 to 12.7 per 1,000 inhabitants per year). Between 2013 and 2014, the incidence rate of hospitalization for acute bronchiolitis decreased by 8% (12.5 to 11.5 per 1,000 inhabitants per year). However, in the second year of the program, hospitalization rate increased again by 10% (12.7 per 1,000 inhabitants per years). CONCLUSIONS: Acute bronchiolitis presented increasing rates of hospitalization over the study period. Hospitalization incidence for acute bronchiolitis declined one year after the implementation of palivizumab but increased again in the second year of the program.


Subject(s)
Antiviral Agents/therapeutic use , Bronchiolitis/drug therapy , Bronchiolitis/epidemiology , Hospitalization/trends , Palivizumab/therapeutic use , Acute Disease , Antiviral Agents/administration & dosage , Brazil/epidemiology , Bronchiolitis/immunology , Bronchiolitis/virology , Female , Health Plan Implementation/methods , Humans , Immunization Programs/methods , Incidence , Infant , Infant, Newborn , Male , Palivizumab/administration & dosage , Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Viruses/immunology , Retrospective Studies , Time Factors
7.
J. bras. pneumol ; J. bras. pneumol;46(3): e20180376, 2020. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1090812

ABSTRACT

RESUMO Objetivo Uma proporção significativa de lactentes desenvolve sibilância recorrente após um evento de bronquiolite aguda (BA). Estudos recentes demonstraram proteção para sibilância recorrente e menor morbidade respiratória em lactentes tratados com azitromicina durante uma crise de sibilância. O objetivo do presente estudo foi testar a hipótese de que a administração de azitromicina durante um evento BA reduz sibilos e reinternações hospitalares subsequentes. Métodos Trata-se de uma análise secundária de um estudo randomizado, duplo-cego, controlado por placebo, incluindo dados não publicados de sibilância e hospitalizações durante os seis meses iniciais após a internação por bronquiolite aguda. O estudo foi realizado em um hospital universitário terciário. Os bebês (<12 meses de idade) hospitalizados com BA foram randomizados para receber azitromicina ou placebo, administrados por via oral, por sete dias. As famílias foram contatadas por telefone aos três e seis meses após o evento agudo inicial, e responderam a um questionário padronizado para identificar sibilos recorrentes e reinternações hospitalares. Resultados Cento e quatro pacientes foram incluídos (grupo Azitromicina, n=50; grupo Placebo, n=54). Considerando o total de pacientes contatados com sucesso três meses após a hospitalização (n=70), a taxa de recorrência de sibilância no grupo da azitromicina foi significativamente menor do que no grupo placebo (RR=0,48; CI=0,24-0.98; p=0,038). Conclusões A azitromicina reduziu significativamente o risco de sibilância subsequente entre zero e três meses após a admissão hospitalar por bronquiolite aguda.


ABSTRACT Objective A significant proportion of the infants developed recurrent wheezing after an acute bronchiolitis (AB) event. Recent studies have demonstrated protection for recurrent wheeze and lower respiratory morbidity in infants treated with azithromycin during an acute respiratory wheezing. The aim of the present study was to test the hypothesis that administration of azithromycin during an AB event reduces subsequent wheezing and hospital re-admissions. Methods This is a secondary analysis of a randomized, double-blinded, placebo-controlled trial, including unpublished data of wheezing and hospitalizations during the initial 6 months following admission for acute viral bronchiolitis. The study was performed in a tertiary University hospital. Infants (<12 months of age) hospitalized with AB were randomized to receive either azithromycin or placebo, administered orally, for 7 days. Families were contacted by telephone at 3 and 6 months after the initial acute event and answered to a standardized questionnaire in order to identify recurrent wheezing and hospital readmissions. Results One hundred and four patients were included (Azithromycin group, n= 50; placebo group, n=54). Considering the total of patients contacted 3 months after hospitalization (n=70), the recurrence rate of wheezing in the azithromycin group was significantly lower than in the placebo group (RR = 0.48; CI = 0.24-0.98; p = 0.038). Conclusion Azithromycin significantly reduces the risk of subsequent wheezing between 0 and 3 months after hospital admission due to acute bronchiolitis irrespective of the presence of respiratory syncytial virus.


Subject(s)
Humans , Infant , Bronchiolitis/drug therapy , Azithromycin/therapeutic use , Recurrence , Bronchiolitis/diagnosis , Respiratory Sounds , Treatment Outcome , Azithromycin/administration & dosage , Hospitalization
8.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 38: e2018120, 2020. tab, graf
Article in English, Portuguese | LILACS, Sec. Est. Saúde SP | ID: biblio-1136733

ABSTRACT

ABSTRACT Objective: To evaluate the trend of hospitalization for acute bronchiolitis in infants under one year of age, in the past eight years and after the implementation of the palivizumab immunization program in Brazil. Methods: The study is a retrospective analysis of data on infants younger than one year of age, who were hospitalized with acute bronchiolitis between 2008 and 2015 in Brazil. The Brazilian National Health System database was used. The rates of hospitalization in the pre-implementation (2008-2012) and post-implementation (2014-2015) periods of the palivizumab immunization program were evaluated. The total number of admissions in the same period was used as a comparison. Results: Between January 2008 and December 2015, 263,679 hospitalizations for bronchiolitis were recorded in infants younger than one year of age, 60% represented by boys. The incidence of hospitalization for bronchiolitis increased by 49% over this period (8.5 to 12.7 per 1,000 inhabitants per year). Between 2013 and 2014, the incidence rate of hospitalization for acute bronchiolitis decreased by 8% (12.5 to 11.5 per 1,000 inhabitants per year). However, in the second year of the program, hospitalization rate increased again by 10% (12.7 per 1,000 inhabitants per years). Conclusions: Acute bronchiolitis presented increasing rates of hospitalization over the study period. Hospitalization incidence for acute bronchiolitis declined one year after the implementation of palivizumab but increased again in the second year of the program.


RESUMO Objetivo: Avaliar a tendência de hospitalização por bronquiolite aguda (BA) em lactentes menores de um ano de idade nos últimos oito anos no Brasil e, secundariamente, após a implementação do programa de imunização por palivizumabe. Métodos: Análise retrospectiva dos dados de lactentes menores de um ano de idade, hospitalizados com diagnóstico de BA entre 2008 e 2015 no Brasil, utilizando o banco de dados do Sistema Único de Saúde (SUS). Foram avaliadas as taxas de hospitalização nos períodos pré-implementação (2008-2012) e pós-implementação (2014-2015) do programa de imunização por palivizumabe. O número total de internações no mesmo período foi utilizado como comparação. Resultados: Entre janeiro de 2008 e dezembro 2015 foram registradas 263.679 internações por bronquiolite em lactentes menores de um ano de idade, 60% representado por meninos. A incidência de hospitalização por bronquiolite aumentou em 49% ao longo desse período (8,5 para 12,7 por mil ­habitantes/­ano). Entre 2013 e 2014, a taxa de incidência de hospitalização por BA diminuiu 8% (12,5 para 11,5 por mil habitantes/ano). Porém, no segundo ano do programa, a taxa de internação aumentou novamente em 10% (12,7 por mil habitantes/ano). Conclusões: A BA apresentou taxas de hospitalização crescente ao longo do período estudado. A incidência de hospitalizações de BA apresentou declínio um ano após a implementação de palivizumabe e retornou à tendência crescente no segundo ano do programa.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Antiviral Agents/therapeutic use , Bronchiolitis/drug therapy , Bronchiolitis/epidemiology , Palivizumab/therapeutic use , Hospitalization/trends , Antiviral Agents/administration & dosage , Respiratory Syncytial Viruses/immunology , Time Factors , Brazil/epidemiology , Bronchiolitis/immunology , Bronchiolitis/virology , Acute Disease , Incidence , Retrospective Studies , Respiratory Syncytial Virus Infections/prevention & control , Immunization Programs/methods , Palivizumab/administration & dosage , Health Plan Implementation/methods
9.
J. bras. pneumol ; J. bras. pneumol;44(6): 498-504, Nov.-Dec. 2018. tab, graf
Article in English | LILACS | ID: biblio-984605

ABSTRACT

ABSTRACT Objectives: To characterize the main identified mutations on cystic fibrosis transmembrane conductance regulator (CFTR) in a group of children and adolescents at a cystic fibrosis center and its association with the clinical and laboratorial characteristics. Method: Descriptive cross-sectional study including patients with cystic fibrosis who had two alleles identified with CFTR mutation. Clinical, anthropometrical, laboratorial and pulmonary function (spirometry) data were collected from patients' records in charts and described with the results of the sample genotyping. Results: 42 patients with cystic fibrosis were included in the study. The most frequent mutation was F508del, covering 60 alleles (71.4%). The second most common mutation was G542X (six alleles, 7.1%), followed by N1303K and R1162X mutations (both with four alleles each). Three patients (7.14%) presented type III and IV mutations, and 22 patients (52.38%) presented homozygous mutation for F508del. Thirty three patients (78.6%) suffered of pancreatic insufficiency, 26.2% presented meconium ileus, and 16.7%, nutritional deficit. Of the patients in the study, 59.52% would be potential candidates for the use of CFTR-modulating drugs. Conclusions: The mutations of CFTR identified more frequently were F508del and G542X. These are type II and I mutations, respectively. Along with type III, they present a more severe cystic fibrosis phenotype. More than half of the sample (52.38%) presented homozygous mutation for F508del, that is, patients who could be treated with Lumacaftor/Ivacaftor. Approximately 7% of the patients (7.14%) presented type III and IV mutations, therefore becoming candidates for the treatment with Ivacaftor.


RESUMO Objetivos: Caracterizar as principais mutações identificadas no cystic fibrosis transmembrane conductance regulator (CFTR) em um grupo de crianças e adolescentes de um centro multidisciplinar de tratamento de fibrose cística e sua associação com características clínicas e laboratoriais. Método: Estudo transversal descritivo que incluiu pacientes com fibrose cística que possuíam dois alelos identificados com mutação no CFTR. Dados clínicos, antropométricos, laboratoriais e de função pulmonar (espirometria) foram coletados de registros em prontuários e descritos com os resultados de genotipagem da amostra. Resultados: Foram incluídos 42 pacientes com fibrose cística. A mutação mais frequente foi a F508del, abrangendo 60 alelos (71,4%). A segunda mutação mais comum foi a G542X (seis alelos, 7,1%), seguida das mutações N1303K e R1162X (ambas com quatro alelos cada uma). Três pacientes (7,14%) apresentaram mutações de classes III e IV, e 22 pacientes (52,38%), homozigose para F508del. Trinta e três pacientes (78,6%) tinham insuficiência pancreática, 11 (26,2%) apresentaram íleo meconial e sete (16,7%) déficit nutricional. Dos pacientes do estudo, 59,52% seriam potenciais candidatos ao uso de fármacos moduladores de CFTR. Conclusões: As mutações do CFTR identificadas com mais frequência foram F508del e G542X, as quais são mutações pertencentes às classes II e I, respectivamente, e que, juntamente à classe III, conferem um fenótipo de fibrose cística com mais gravidade. Mais da metade (52,38%) da amostra apresentava F508del em homozigose, população candidata ao novo tratamento com Lumacaftor/Ivacaftor. Aproximadamente 7% dos pacientes apresentavam mutações de classes III e IV, sendo candidatos ao tratamento com Ivacaftor.


Subject(s)
Humans , Male , Female , Child , Adolescent , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/genetics , Mutation/genetics , Phenotype , Cross-Sectional Studies
10.
J Bras Pneumol ; 44(6): 498-504, 2018.
Article in English, Portuguese | MEDLINE | ID: mdl-30726326

ABSTRACT

OBJECTIVES: To characterize the main identified mutations on cystic fibrosis transmembrane conductance regulator (CFTR) in a group of children and adolescents at a cystic fibrosis center and its association with the clinical and laboratorial characteristics. METHOD: Descriptive cross-sectional study including patients with cystic fibrosis who had two alleles identified with CFTR mutation. Clinical, anthropometrical, laboratorial and pulmonary function (spirometry) data were collected from patients' records in charts and described with the results of the sample genotyping. RESULTS: 42 patients with cystic fibrosis were included in the study. The most frequent mutation was F508del, covering 60 alleles (71.4%). The second most common mutation was G542X (six alleles, 7.1%), followed by N1303K and R1162X mutations (both with four alleles each). Three patients (7.14%) presented type III and IV mutations, and 22 patients (52.38%) presented homozygous mutation for F508del. Thirty three patients (78.6%) suffered of pancreatic insufficiency, 26.2% presented meconium ileus, and 16.7%, nutritional deficit. Of the patients in the study, 59.52% would be potential candidates for the use of CFTR-modulating drugs. CONCLUSIONS: The mutations of CFTR identified more frequently were F508del and G542X. These are type II and I mutations, respectively. Along with type III, they present a more severe cystic fibrosis phenotype. More than half of the sample (52.38%) presented homozygous mutation for F508del, that is, patients who could be treated with Lumacaftor/Ivacaftor. Approximately 7% of the patients (7.14%) presented type III and IV mutations, therefore becoming candidates for the treatment with Ivacaftor.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/genetics , Mutation/genetics , Adolescent , Child , Cross-Sectional Studies , Female , Humans , Male , Phenotype
11.
Respir Med ; 121: 21-25, 2016 12.
Article in English | MEDLINE | ID: mdl-27888987

ABSTRACT

BACKGROUND: Since June 2011, the Brazilian health system started providing asthma medications (beclomethasone and salbutamol), totally free of charge to patients with asthma. The aim of this study was to evaluate the impact of the provision of free asthma medications on hospital admissions for asthma in Brazil, using a national hospitalization database (DATASUS), comparing the incidence of hospital admissions before and after the free supply of these drugs. METHODS: Admissions of patients with 1-49 years of age by the Brazilian public health system with the diagnosis of asthma were compared pre (2008-2010) and post (2012-2014) provision of free medicines (beclomethasone and salbutamol). The number of hospital admissions due to asthma and non-respiratory diseases, as well as the amount spent with asthma hospitalization, were obtained from DATASUS, the Brazilian government open-access public health database system. RESULTS: Admission rates for asthma significantly decreased from 90.09/100.000 (2008-2010) to 59.85/100.000 (2012-2014), when the period pre and post provision of free medicines were compared [OR 0.67 (CI 0.48-0.92)]. Non-respiratory admission rates remained stable, when both periods were also compared. CONCLUSION: Asthma hospitalization rates significantly decreased in the three-year period after the provision of free medicines to treat asthma. Our findings suggest that the provision of free medications for asthma may have a particular public health impact by its own in developing countries.


Subject(s)
Anti-Asthmatic Agents/economics , Asthma/drug therapy , Drug Costs/statistics & numerical data , Hospitalization/statistics & numerical data , Adolescent , Adult , Age Distribution , Albuterol/economics , Albuterol/therapeutic use , Anti-Asthmatic Agents/therapeutic use , Asthma/economics , Asthma/epidemiology , Beclomethasone/economics , Beclomethasone/therapeutic use , Brazil/epidemiology , Child , Child, Preschool , Databases, Factual , Female , Glucocorticoids/economics , Glucocorticoids/therapeutic use , Health Care Costs/statistics & numerical data , Health Care Costs/trends , Hospitalization/trends , Humans , Infant , Male , Middle Aged
12.
Rev. bras. ter. intensiva ; 24(2): 119-129, abr.-jun. 2012. tab
Article in Portuguese | LILACS | ID: lil-644641

ABSTRACT

Recomendações para a atuação do fisioterapeuta em unidade de terapia intensiva pediátrica e neonatal são fundamentais, pois esses profissionais são responsáveis pela reabilitação de pacientes graves. A reabilitação inclui desde a avaliação e prevenção de alterações cinético funcionais às intervenções de tratamento (fisioterapia respiratória e/ou motora), controle e aplicação de gases medicinais, cuidados da ventilação pulmonar mecânica invasiva e não invasiva, protocolos de desmame e extubação, insuflação traqueal de gás, protocolo de insuflação/desinsuflação do balonete intratraqueal, aplicação de surfactante, entre outros. Com o objetivo de propiciar a recuperação do doente e seu retorno às atividades funcionais. Nesse contexto, essas recomendações têm o objetivo de orientar os fisioterapeutas sobre algumas intervenções de prevenção/tratamento de fisioterapia respiratória (desobstrução das vias aéreas; reexpansão pulmonar; posicionamento no leito; aspiração das vias aéreas; inaloterapia; tosse assistida), que auxiliam no processo de reabilitação de pacientes pediátricos e neonatais em unidade de terapia intensiva em ventilação pulmonar mecânica e até 12 horas após a extubação.


Developing guidelines for the role of the physiotherapist in neonatal and pediatric intensive care units is essential because these professionals are responsible for the rehabilitation of critically ill patients. Rehabilitation includes the evaluation and prevention of functional kinetic alterations, application of treatment interventions (respiratory and/or motor physiotherapy), control and application of medical gases, care of mechanical ventilation, weaning and extubation, tracheal gas insufflation, inflation/deflation of the endotracheal cuff protocol, and surfactant application, aiming to allow patients to have a full recovery and return to their functional activities. In this article, we present guidelines that are intended to guide the physiotherapist in some of the prevention/treatment interventions in respiratory therapy (airway clearance, lung expansion, position in bed, airway suction, drug inhalation, and cough assist), which help in the rehabilitation process of newborns and children in intensive care units during mechanical ventilation and up to 12 hours following extubation.

13.
Rev Bras Ter Intensiva ; 24(2): 119-29, 2012 Jun.
Article in English, Portuguese | MEDLINE | ID: mdl-23917758

ABSTRACT

Developing guidelines for the role of the physiotherapist in neonatal and pediatric intensive care units is essential because these professionals are responsible for the rehabilitation of critically ill patients. Rehabilitation includes the evaluation and prevention of functional kinetic alterations, application of treatment interventions (respiratory and/or motor physiotherapy), control and application of medical gases, care of mechanical ventilation, weaning and extubation, tracheal gas insufflation, inflation/deflation of the endotracheal cuff protocol, and surfactant application, aiming to allow patients to have a full recovery and return to their functional activities. In this article, we present guidelines that are intended to guide the physiotherapist in some of the prevention/treatment interventions in respiratory therapy (airway clearance, lung expansion, position in bed, airway suction, drug inhalation, and cough assist), which help in the rehabilitation process of newborns and children in intensive care units during mechanical ventilation and up to 12 hours following extubation.

14.
Sci. med ; 21(1)jan.-mar. 2011. tab
Article in English | LILACS | ID: lil-593778

ABSTRACT

Aims: The purpose of the present study was to investigate the viability of the use of piglets as experimental model of newborn chest physiotherapy.Methods: Five piglets (1-2 days old) were studied. The animals received anesthesia and analgesia and were ventilated with positive pressure, on 100% oxygen. All piglets received chest physiotherapy protocol of manual vibration.Results: All five animals presented stable physiological parameters during the preparation phase and the physiotherapy protocol application.Conclusions: We conclude that piglets are a viable model for studies of chest physiotherapy in mechanically ventilated newborns.


Objetivos: o objetivo do presente estudo foi investigar a viabilidade do uso de suínos como modelo experimental de fisioterapia respiratória em recém-nascidos.Métodos: foram estudados cinco suínos recém-nascidos (1-2 dias de idade). Os animais receberam anestesia e analgesia e foram ventilados com pressão positiva, com oxigênio a 100%. Todos os animais receberam o protocolo de fisioterapia respiratória de vibração manual.Resultados: todos os cinco animais apresentaram estabilidade dos parâmetros fisiológicos durante a fase de preparação e aplicação do protocolo de fisioterapia.Conclusões: concluímos que os suínos representam um modelo viável para estudos de fisioterapia respiratória em recém-nascidos em ventilação mecânica.


Subject(s)
Animals , Infant, Newborn , Models, Animal , Respiration, Artificial , Respiratory Therapy
15.
Mundo saúde (Impr.) ; 34(2): 158-164, abr.-jun. 2010. graf, tab
Article in Portuguese | LILACS | ID: lil-562036

ABSTRACT

A instabilidade postural com a ocorrência de quedas é uma característica do envelhecimento, representando um motivo de preocupação para os idosos, pois pode acarretar incapacidade física e perda da independência. O objetivo deste estudo foi avaliar o risco de quedas em idosas que praticam atividades físicas e idosas sedentárias. Foram avaliadas mulheres acima de 60 anos ativas e sedentárias quanto ao risco de quedas utilizando os testes Timed Up and Go, Escala de Berg e Performance Oriented Mobility Assessment. Como resultados teve-se que o grupo de mulheres ativas obteve melhores desempenhos nos teste Timed Up And Go (p igual a 0,001), Escala de Berg (p igual a 0,002) e Performance Oriented Mobility Assessement (p igual a 0,002) do que as mulheres do grupo sedentárias. O relato de dor nos pés emedo de cair foi maior no grupo de idosas sedentárias. Concluiu-se que as idosas sedentárias apresentaram menor mobilidade funcional, maiores déficits no equilíbrio e alterações na marcha quando comparadas a idosas que praticavam exercício físico regularmente. Dessa forma, concluímos que a prática de exercício físico contribuiu para a redução do risco de quedas no grupo estudado.


Postural instability with occurrence of falls is a characteristic of aging, representing a reason of worry for old people, because it can cause physical incapacity and loss of independence. The objective of this study was to evaluate the risk of falls of old women practicing physical exercises and sedentary ones. Women more than 60 years old, both active and sedentary were tested regarding the risk of falling using Timed Up and Go, Berg Scale and Performance Oriented Mobility Assessment. The following results were obtained: the group of active women had better performances in tests Timed Up And Go (p equal to 0.001), Scale of Berg (p equal to 0.002)) and Performance Oriented Mobility Assessment (p equal to 0.002) than women of the sedentary group. The story of pain in the feet and fear of falling was greater in the group of sedentary women. One thus concluded that sedentary women presented less functional mobility and more balance deficits, as well as alterations in marching when compared to those which practiced physical exercise regularly. We conclude that thepractice of physical exercises contributed to reducing the risk of falls in the studied group.


La instabilidad postural con ocurrencia de caídas es una característica del envejecimiento, representando un motivo de preocupación para los envejecidos, porque puede acarrear incapacidad física y pérdida de independencia. El objetivo de este estudio fue evaluar el riesgo de caídas en envejecidas practicantes de actividades físicas y sedentarias. Se evaluaran mujeres de más de 60 años, activas y sedentarias en cuanto al riesgo de caídas de promedio os tests Timed Up and Go, Escala de Berg y Performance Oriented Mobility Assessment. Se lograran los siguientes resultados: el grupo de mujeres activas obtuvo desempeños mejores en los tests Timed Up And Go (p igual a 0,001), Escala de Berg (p igual a 0,002)) y Performance Oriented Mobility Assessment (p igual a 0,002) que las mujeres del grupo sedentario. El relato de dolor en los pies y de miedo de caer fue mayor en el grupo de sedentarias. Se concluyó que las sedentarias presentaron menor movilidad funcional y mayores déficits de equilibrio, así bien alteraciones en la marcha cuando comparadas a lasque practicaban regularmente ejercicio físico. Se concluye que la práctica de ejercicios físicos contribuyó para la reducción del riesgo de caídas en lo grupo estudiado.


Subject(s)
Aged , Accidental Falls , Health of the Elderly , Motor Activity , Sedentary Behavior
16.
Fisioter. pesqui ; 14(2): 91-97, maio-ago. 2007. ilus
Article in Portuguese | LILACS | ID: lil-469896

ABSTRACT

Estudos de revisão sobre fisioterapia respiratória neonatal têm apresentado resultados sem detalhar adequadamente o delineamento e o rigor metodológico com que os trabalhos revisados foram realizados. Visando conhecer a segurança e eficácia da fisioterapia em recém-nascidos pré-termo, internados em unidades de terapia intensiva neonatal...


Literature reviews on chest physical therapy in premature infants often present results without providing adequate methodology detailing and rigour of the reviewed studies. In order to know safe ad effective chest physical therapy for newborns in neonatal intensive therapy...


Subject(s)
Breathing Exercises , Infant, Newborn , Intensive Care Units, Neonatal
17.
Article in Portuguese | LILACS | ID: lil-417980

ABSTRACT

Desde quando adquiriram caráter médico-assistencial, durante o século 18, as práticas hospitalares evoluíram sem considerar as características e necessidades especiais da população pediátrica até meados do século 20. Em 1959, através da Declaração dos Direitos da Criança, proclamada pela Assembléia Geral das Nações Unidas, novos paradigmas de atenção à infância foram lançados. Já em 1979, quando da inauguração do Serviço de Internação Pediátrica do Hospital de Clínicas de Porto Alegre, destacam-se a introdução do serviço de recreação terapêutica e a possibilidade de acompanhamento dos pais durante todo o período de internação, mesmo nas unidades de terapia intensiva. Este estudo buscou, através da reconstrução de uma parcela da história da instituição, identificar permissões e práticas que nos aproximam dos conceitos expressos na legislação brasileira relativa aos Direitos da Criança Hospitalizada, em vigor desde 1995, tentando compreender de que forma esses espaços foram criados, estabeleceram-se e consolidaram-se, bem como as motivações que conduziram sua aplicação. Para tanto, foram realizadas entrevistas com professores e funcionários diretamente envolvidos em projetos e serviços que viabilizaram a aplicação desses direitos. Assim, verificou-se que esses direitos foram implantados paulatinamente, vinculados à prática assistencial, desde a criação do serviço e antes da formulação de legislação específica


Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Child Advocacy/legislation & jurisprudence , Hospitals, Pediatric , Length of Stay , Child , Child, Preschool
SELECTION OF CITATIONS
SEARCH DETAIL